Barrie Wilkinson
Gründer bei Isomerase Therapeutics Ltd.
Profil
Barrie Wilkinson is the founder and Non-Executive Director at Isomerase Therapeutics Ltd.
founded in 2012.
He was also a Vice President-Research at Biotica Technology Ltd.
from 2001 to 2013.
Dr. Wilkinson received his undergraduate degree in 1990 and his doctorate in 1993 from the University of Leeds.
Aktive Positionen von Barrie Wilkinson
| Unternehmen | Position | Beginn |
|---|---|---|
Isomerase Therapeutics Ltd.
 Isomerase Therapeutics Ltd. BiotechnologyHealth Technology Isomerase Therapeutics Ltd. operates as a drug discovery and development company. It specializes in biosynthetic medicinal chemistry and synthetic biology, microbial natural products, microbial natural products, and semisynthetic chemistry. The company was founded by Barrie Wilkinson, Matthew Gregory, and Steven Moss in 2012 and is headquartered in Cambridge, the United Kingdom. | Gründer | 01.01.2012 |
Ehemalige bekannte Positionen von Barrie Wilkinson
| Unternehmen | Position | Ende |
|---|---|---|
Biotica Technology Ltd.
 Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB. | Technik-/Wissenschafts-/F&E-Leiter | 12.03.2013 |
Ausbildung von Barrie Wilkinson
| University of Leeds | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Biotica Technology Ltd.
Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB. | Health Technology |
Isomerase Therapeutics Ltd.
Isomerase Therapeutics Ltd. BiotechnologyHealth Technology Isomerase Therapeutics Ltd. operates as a drug discovery and development company. It specializes in biosynthetic medicinal chemistry and synthetic biology, microbial natural products, microbial natural products, and semisynthetic chemistry. The company was founded by Barrie Wilkinson, Matthew Gregory, and Steven Moss in 2012 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
